Bliss GVS Pharma Share Price
Bliss GVS Pharma Share Price Today
As of 5 Jul 2026, Bliss GVS Pharma share price is ₹505.95. The stock opened at ₹505.00, compared to its previous close of ₹527.10. During today's trading session, Bliss GVS Pharma share price moved in the range of ₹500.75 to ₹525.00, with an average price of ₹512.88 for the day. Looking at its last 52-week, the stock has touched a low of ₹118.00 and a high of ₹553.00. On the performance front, Bliss GVS Pharma share price has increased by 210.74% over the last six months and is up 223.68% on a year-on-year basis.
Bliss GVS Pharma Returns Calculator
Bliss GVS Pharma Shareholder Returns
Bliss GVS Pharma Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Bliss GVS Pharma Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹809.73 | ₹770.24 | ₹751.59 | ₹747.45 |
| Other Income | ₹36.49 | ₹28.74 | ₹17.79 | ₹31.49 |
| Total Revenue | ₹846.22 | ₹798.98 | ₹769.37 | ₹778.95 |
| Total Expenses | ₹720.58 | ₹652.91 | ₹663.30 | ₹651.19 |
| Profit Before Tax | ₹125.64 | ₹116.87 | ₹106.07 | ₹54.17 |
| Tax | ₹35.38 | ₹35.29 | ₹29.34 | ₹31.04 |
| Profit After Tax | ₹90.26 | ₹81.58 | ₹76.73 | ₹23.13 |
| EPS - Basic | ₹8.02 | ₹7.23 | ₹6.83 | ₹1.46 |
| EPS - Diluted | ₹7.95 | ₹7.11 | ₹6.72 | ₹1.43 |
Cash Flow · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹189.59 | ₹125.64 | ₹146.07 | ₹106.07 |
| Income before WC changes | ₹285.46 | ₹196.38 | ₹184.24 | ₹163.99 |
| Change in Assets | -₹158.32 | -₹53.98 | -₹35.62 | -₹75.86 |
| Change in Liabilities | ₹53.88 | ₹2.52 | -₹10.95 | -₹9.26 |
| Change in WC | -₹104.45 | -₹51.46 | -₹46.57 | -₹85.12 |
| Cash flow from Operations | ₹138.72 | ₹105.91 | ₹102.82 | ₹34.31 |
| Cash flow from Investing | -₹38.28 | -₹75.59 | -₹83.19 | -₹7.75 |
| Cash flow from Financing | -₹89.21 | -₹30.20 | -₹20.89 | -₹24.94 |
| Total Cash Flow | ₹11.23 | ₹0.13 | -₹1.27 | ₹1.62 |
| Cash (Start of the year) | ₹23.82 | ₹23.59 | ₹25.01 | ₹21.99 |
| Cash (End of the year) | ₹35.14 | ₹23.82 | ₹23.59 | ₹25.01 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹474.33 | ₹400.72 | ₹459.49 | ₹331.89 |
| Current Assets | ₹826.51 | ₹810.87 | ₹697.37 | ₹776.86 |
| Total Assets | ₹1,300.84 | ₹1,211.59 | ₹1,156.85 | ₹1,108.75 |
| Current Liabilities | ₹171.72 | ₹157.41 | ₹193.26 | ₹233.09 |
| Net Current Asset | ₹654.79 | ₹653.47 | ₹504.11 | ₹543.77 |
| Non-Current Liabilities | ₹37.28 | ₹51.20 | ₹46.17 | ₹29.20 |
| Equity Capital | ₹1,091.85 | ₹1,002.98 | ₹917.42 | ₹846.46 |
| Total Equity & Liabilities | ₹1,300.84 | ₹1,211.59 | ₹1,156.85 | ₹1,108.75 |
Income Statement · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹729.81 | ₹667.20 | ₹605.46 | ₹598.34 |
| Other Income | ₹43.72 | ₹36.22 | ₹33.50 | ₹50.77 |
| Total Revenue | ₹773.53 | ₹703.42 | ₹638.96 | ₹649.11 |
| Total Expenses | ₹637.91 | ₹609.25 | ₹527.62 | ₹533.41 |
| Profit Before Tax | ₹133.46 | ₹94.17 | ₹70.26 | ₹115.69 |
| Tax | ₹36.59 | ₹25.20 | ₹19.61 | ₹30.21 |
| Profit After Tax | ₹96.87 | ₹68.97 | ₹50.64 | ₹85.48 |
| EPS - Basic | ₹9.17 | ₹6.56 | ₹4.85 | ₹8.23 |
| EPS - Diluted | ₹9.00 | ₹6.50 | ₹4.77 | ₹8.10 |
Cash Flow · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹133.46 | ₹94.17 | ₹111.34 | ₹115.69 |
| Income before WC changes | ₹203.80 | ₹150.61 | ₹155.59 | ₹157.11 |
| Change in Assets | -₹82.79 | -₹23.72 | -₹31.70 | -₹67.36 |
| Change in Liabilities | ₹40.61 | ₹0.64 | -₹12.38 | -₹8.23 |
| Change in WC | -₹42.18 | -₹23.08 | -₹44.08 | -₹75.58 |
| Cash flow from Operations | ₹123.16 | ₹97.21 | ₹82.17 | ₹43.81 |
| Cash flow from Investing | -₹51.40 | -₹77.87 | -₹65.84 | -₹12.97 |
| Cash flow from Financing | -₹75.37 | -₹26.56 | -₹20.76 | -₹26.05 |
| Total Cash Flow | -₹3.61 | -₹7.23 | -₹4.43 | ₹4.79 |
| Cash (Start of the year) | ₹6.85 | ₹14.17 | ₹18.60 | ₹13.82 |
| Cash (End of the year) | ₹3.33 | ₹6.85 | ₹14.17 | ₹18.60 |
Balance Sheet · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹517.82 | ₹454.40 | ₹378.04 | ₹410.04 |
| Current Assets | ₹826.36 | ₹765.74 | ₹772.23 | ₹729.65 |
| Total Assets | ₹1,344.18 | ₹1,220.14 | ₹1,150.27 | ₹1,139.69 |
| Current Liabilities | ₹168.59 | ₹125.00 | ₹114.89 | ₹153.36 |
| Net Current Asset | ₹657.77 | ₹640.74 | ₹657.34 | ₹576.30 |
| Non-Current Liabilities | ₹20.40 | ₹36.51 | ₹46.94 | ₹49.34 |
| Equity Capital | ₹1,155.19 | ₹1,058.63 | ₹988.44 | ₹937.00 |
| Total Equity & Liabilities | ₹1,344.18 | ₹1,220.14 | ₹1,150.27 | ₹1,139.69 |
About Bliss GVS Pharma
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products, other healthcare products, and therapeutic index. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, oral solids, and others. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, NOVOGLIP-5, GVZOLE, and DOXYCYCLINE.
Bliss GVS Pharma Financial Highlights
- Revenue: Bliss GVS Pharma reported revenue of ₹1,000.64 crore in FY26 vs ₹846.22 crore in FY25. It showed an increase of 18.25% on a yearly basis.
- Operating Profit: Bliss GVS Pharma reported an operating profit of ₹189.59 crore in FY26 vs ₹125.64 crore in FY25. It showed an increase of 50.90% on a year-on-year basis.
- Net Profit: Bliss GVS Pharma reported a net profit of ₹134.73 crore in FY26 vs ₹90.26 crore in FY25. It showed an increase of 49.27% on a yearly basis.
Bliss GVS Pharma Quarterly Result Highlights
- Bliss GVS Pharma reported revenue of ₹268.15 crore in Mar 2026, compared with ₹236.71 crore in Dec 2025, representing an increase of 13.28% on a quarter-on-quarter (QoQ) basis.
- Bliss GVS Pharma reported an operating profit of ₹44.95 crore in Mar 2026, compared with ₹40.90 crore in Dec 2025, representing an increase of 9.90% on a quarter-on-quarter (QoQ) basis.
- Bliss GVS Pharma reported a profit of ₹37.00 crore in Mar 2026, compared with ₹24.78 crore in Dec 2025, reflecting an increase of 49.31% on a QoQ basis.
- The earnings per share (EPS) of Bliss GVS Pharma stood at ₹8.02 during Mar 2026.
Similar Stocks
FAQs on Bliss GVS Pharma Share Price
What is Bliss GVS Pharma share price today?
Bliss GVS Pharma share price is ₹505.95 as on 03 Jul, 2026, 15:48 IST.
How has the Bliss GVS Pharma share price performed in the past?
In the last 1 year, Bliss GVS Pharma delivered a return of 223.68%. The Bliss GVS Pharma share price hit a high of ₹553.00 and low of ₹118.00.
How much is the Mutual Fund shareholding in Bliss GVS Pharma shares?
The Mutual Fund Shareholding in Bliss GVS Pharma was 0.00% at the end of Mar 2026.
What is the the 52-week high and low of Bliss GVS Pharma shares ?
The 52-week high and low of Bliss GVS Pharma share is ₹553.00 and ₹118.00 as of 03 Jul, 2026.
What is the market cap of Bliss GVS Pharma?
The market capitalisation of Bliss GVS Pharma is ₹5,583.86 Crores as on 03 Jul, 2026.
What are the stock symbols of Bliss GVS Pharma?
The stock symbol of Bliss GVS Pharma is BLISSGVS on the NSE, 506197 on the BSE, and the ISIN is INE416D01022.
What was yesterday's closing price of Bliss GVS Pharma shares ?
Bliss GVS Pharma shares closed yesterday at ₹527.10 on NSE & ₹526.50 on BSE
How to buy Bliss GVS Pharma shares?
To buy Bliss GVS Pharma shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Bliss GVS Pharma shares on Holidays?
No, shares of Bliss GVS Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Bliss GVS Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Bliss GVS Pharma?
The PE and PB ratio of Bliss GVS Pharma is 17.65 and 1.91 respectively, as on 03 Jul, 2026, 15:48 IST.